D-1837-2019 Class I Terminated
FDA drug recall D-1837-2019 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Jul 9, 2019 and is designated Class I. Reason for recall: Failed dissolution specifications : failed results at the 3-month stability time point. The recall status is terminated (terminated May 7, 2021). Affected quantity: 11,412 cartons/34,236 blister cards/28 tablets each card.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 7, 2019
- Initiation Date
- Jul 9, 2019
- Termination Date
- May 7, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 11,412 cartons/34,236 blister cards/28 tablets each card
Product description
Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/0.02 mg, packaged into a carton containing 3 blister cards each blister card contains 28-film coated, biconvex tablets, Rx Only, Manufactured by: Cyndea Pharma, S.L., Olvega (Soria), 42110 Spain, Distributed by: Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, 21801 USA, NDC 59746-763-43
Reason for recall
Failed dissolution specifications : failed results at the 3-month stability time point.
Distribution pattern
USA Nationwide
Code information
Lot #: 183222, Exp 11/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1837-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026